Prospective effect of linkers type on the anticancer activity of pemetrexed-monoclonal antibody (atezolizumab) conjugates
F1000Research · 2024
DOI: 10.12688/f1000research.140284.2 ↗Kurz gefasst
Fachartikel in der Zeitschrift F1000Research, 2024. Verfasst von Faten Q Ibraheem und 3 weiteren Autor:innen. Beteiligte Einrichtung: pharmaceutics, Mustansiriyah University, Baghdad, Baghdad Governorate, 10011, Iraq. Hauptthemen laut MEDLINE: Pemetrexed, Antibodies, Monoclonal, Humanized, Antineoplastic Agents. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Conventional chemotherapy results in severe toxic side effects due to affecting normal and cancer cells. The conjugation of chemotherapy with mAb will improve the chemotherapy selectivity towards cancer cells and at the same time will potentiate immune system to detect and kill cancer cells. The aim of the study was to prepare atezolizumab-pemetrexed conjugate using two types of linkers (linker conjugated with -NH2 of lysine amino acid in the mAb).
Methods
This study utilizes (for the first time) the mAb atezolizumab (AtZ) to prepare a new, selective conjugate carrier for pemetrexed (PMX) by using gamma amino butyric acid (GABA) as linker for the first time in comparison to the commonly used linker polyethylene glycol (PEG) using carbodiimide (EDC) / N-hydroxysulfosuccinimide (Sulfo-NHS) zero length cross linker. Stepwise evaluation for PMX-linkers linkage as well as mAb conjugates was evaluated by FTIR, 1HNMR, DSC, LC-MS, gel-electrophoresis as well as the anticancer activity against lung cells A549.
Results
The work revealed that two molecules of GABA combined with PMX, which in turn conjugated with an average ratio of 4:1 with mAb, while one molecule of PEG combined with PMX, which in turn conjugated with mAb in the same average ratio. The IC50 for the prepared PMX-GABA-AtZ conjugate was 0.048 µM, which was much lower than PMX alone, antibody AtZ alone as well as PMX-PEG-AtZ conjugate in a dose and time dependent manner.
Conclusions
The potential use of such conjugate that selectively directed to the overexpressed lung cells antigen in a low dose leading to reduction of serious side effects of PMX and the cost of therapeutically AtZ mAb used.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- pharmaceutics, Mustansiriyah University, Baghdad, Baghdad Governorate, 10011, Iraq.
- pharmaceutics, Al-Farahidi University, Baghdad, Baghdad Governorate, 10011, Iraq.
- pharmacology, Mustansiriyah University, Baghdad, Baghdad Governorate, 10011, Iraq.
- pharmaceutical chemistry, Al-Farahidi University, Baghdad, Baghdad Governorate, 10011, Iraq.
ORCID-Profile: Faten Q Ibraheem, Nidhal K Maraie, Ayad M R Raauf
Zitieren
APA
Ibraheem, F. Q., Maraie, N. K., Al-Sudani, B. T., & Raauf, A. M. R. (2024). Prospective effect of linkers type on the anticancer activity of pemetrexed-monoclonal antibody (atezolizumab) conjugates. F1000Research. https://doi.org/10.12688/f1000research.140284.2
Vancouver
Ibraheem FQ, Maraie NK, Al-Sudani BT, Raauf AMR. Prospective effect of linkers type on the anticancer activity of pemetrexed-monoclonal antibody (atezolizumab) conjugates. F1000Research. 2024. doi:10.12688/f1000research.140284.2
BibTeX
@article{Ibraheem2024,
author = {Ibraheem, Faten Q and Maraie, Nidhal K and Al-Sudani, Basma Talib and Raauf, Ayad M R},
title = {Prospective effect of linkers type on the anticancer activity of pemetrexed-monoclonal antibody (atezolizumab) conjugates},
journal = {F1000Research},
year = {2024},
doi = {10.12688/f1000research.140284.2}
}
EUVIMED